Access Pharmaceuticals (ACCP.ob) is an emerging pharmaceuticals company with a focus on oncology and diabetes.
Access has one FDA approved treatment for oral mucositis (MuGard) which has been launched commercially in Europe and will be launched elsewhere in 2009.
ProLindac, a novel DACH platinum chemotherapy, recently completed a Phase 2a trial in recurrent ovarian cancer and will enter combination trials shortly; ProLindac is partnered in the Far East and ACCP is actively seeking North American and European co-development partners.
Additionally, ACCP has a novel nucleoside analogue, Thiarabine, which will enter Phase 2 leukemia trials this year, a preclinical stage monoclonal antibody (Angiolix) and additional preclinical oncology programs.
Also, ACCP has an oral insulin and oral human growth hormone program which is being developed in a sponsored research agreement with a major pharmaceutical company (and for which ACCP is seeking additional development partnerships).
Specialties
Oncology, Diabetes, Biotechnology, Pharma, Oral Mucositis, Ovarian Cancer, Colorectal Cancer, Platinum Drugs, Leukemia
